Table 1 Baseline clinical characteristics

Age

yrs

71.5 ± 8.9

Gender: Male

n (%)

53 (75.7)

Etiology: HBV/HCV/Alcohol/NASH/etc.

n

10/28/10/16/6

Performance status: 0/1

n

65/5

Child-Pugh score 5:6:7:8:9

n

39:17:9:4:1

Child-Pugh class: A/B

n

56/14

Weight

kg

61.5 ± 12.2

  <  60 kg/≥ 60 kg

37/33

Body mass index

kg/m²

23.3 ± 4.6

Barcelona Clinic Liver Cancer stage: B/C

n

32/38

Macroscopic portal vein invasion: Yes/No

n

24/46

Extrahepatic spread: Yes/No

n

22/48

Up to 7: In/Out

n

36/34

Tumor size:

mm

47.1 ± 38.9

Previous therapy:

 Radiofrequency ablation

n

28

 Transcatheter treatment

n

50

 Molecularly-targeted therapy

n

6

Initial dose of lenvatinib: 4 mg/8 mg/12 mg

n

10/35/25

Hemoglobin

g/dL

12.2 ± 2.12

Platelets

× 10⁴/μl

14.1 ± 6.3

Prothrombin time

%

87.1 ± 19.3

Serum albumin

g/dL

3.7 ± 0.45

BUN

g/dL

20.1 ± 14.3

Serum creatinine

mg/dL

0.86 ± 0.36

Aspartate aminotransferase

IU/L

52.0 ± 30.3

Alanine aminotransferase

IU/L

34.0 ± 23.8

Total bilirubin

g/dL

0.9 ± 0.41

Ammonia

μg/dl

51.2 ± 43.0

α-fetoprotein

ng/mL

12,309 ± 49,567

PIVKA-II

mAU/mL

6083 ± 14,136